Speculation mounts again about a possible Stryker offer for Smith & Nephew now that a 6-month no-bid period has ended.
Medtronic reshapes its diabetes business into 3 divisions 'focused on transforming diabetes care,' CEO Omar Ishrak said this week.
Medtronic (NYSE:MDT) said this week that it realigned its diabetes business to focus on "transforming diabetes care," according to CEO Omar Ishrak.
Medtronic CEO Omar Ishrak, speaking yesterday at LifeScience Alley's annual convention in Minneapolis, defends the pending $43 billion Covidien acquisition.
Here's a look at some of the top Wall Street stories for medical device companies this week: InVivo shares soar on spinal cord study update; Actavis trumps Valeant with $66B offer for Allergan; Medtronic's Q2 results meet The Street; Venture capital investment in medtech grows in Q3
Here's a look at some of the top mergers & acquisitions stories for medical device companies this week: Report: Medtronic readies $10B bond flotation for Covidien deal; Medtech mergers stayed strong in Q3; Sources: Philips attracts private equity bids for lighting unit; Medtronic, Covidien set timetable for shareholders meetings; Report: Actavis may buy Allergan for at least $60 billion
Medtronic's strong fiscal 2nd-quarter results pushed its stock to a 52-week high today.
Shares of Medtronic (NYSE:MDT) hit a 52-week high today on the strength of its 2nd-quarter results, peaking at $72.74 apiece.
MDT shares closed at $72.47 each, for a 4.7% gain on the day.
Medtronic reports fiscal 2nd-quarter sales and earnings in line with expectations on Wall Street.
Medtronic (NYSE:MDT) today reported 2nd-quarter results that met expectations on Wall Street.